Samsung Biologics’ Plant 4 facility (courtesy Samsung)

Sam­sung Bio’s bet on Plant 4 con­tin­ues to pay off with first-quar­ter earn­ings growth

Sam­sung Bi­o­log­ics’ Plant 4 re­mains a worth­while $2 bil­lion in­vest­ment.

The CD­MO said that the fa­cil­i­ty was key in its first-quar­ter gains and will con­tin­ue …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.